RT Journal Article SR Electronic T1 Lower cognitive performance in healthy G2019S LRRK2 mutation carriers JF Neurology JO Neurology FD Lippincott Williams & Wilkins SP 1027 OP 1032 DO 10.1212/WNL.0b013e3182684646 VO 79 IS 10 A1 Thaler, Avner A1 Mirelman, Anat A1 Gurevich, Tanya A1 Simon, Ely A1 Orr-Urtreger, Avi A1 Marder, Karen A1 Bressman, Susan A1 Giladi, Nir YR 2012 UL http://n.neurology.org/content/79/10/1027.abstract AB Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene. Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale. Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007). Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD. AJ=Ashkenazi Jewish; EF=executive function; GDS=Geriatric Depression Scale; MoCA=Montreal Cognitive Assessment test; PD=Parkinson disease; RT=reaction time; UPDRS=Unified Parkinson's Disease Rating Scale